Ractigen Shares Encouraging Clinical Results for RAG-17 in ALS-SOD1 Therapy from Independent Study.

Insulin efsitora alfa, administered weekly, achieves comparable A1C reduction to daily insulin in adults with type 1 diabetes.

Recent findings on the investigational drug BAY 2927088 for HER2-mutant non-small cell lung cancer (NSCLC) showcased at WCLC.

Sep 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

In the TROPION-Lung01 Phase 3 trial, Datopotamab Deruxtecan demonstrated a median overall survival of 14.6 months for patients with advanced nonsquamous non-small cell lung cancer.

KaliVir is able to produce novel, potent oncolytic Vaccinia viruses with high replication ability and enhanced capabilities for intravenous administration and dissemination.

Incendia Therapeutics Begins Phase 1c Trial with First Patient for PRTH-101, an Innovative DDR1 Inhibitor.

Sep 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Viridian Therapeutics Reports Encouraging Topline Results from Phase 3 THRIVE Trial of Veligrotug (VRDN-001) in Thyroid Eye Disease Patients.

The article reported on Phase 2 clinical trial data for the use of the monoclonal antibody Lu AG09222ALD-1910 targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in the treatment of migraine.

Basking Biosciences Administers Initial Dosage to Participants in Phase 2 Study of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke.

In the field of anti-tumor drugs, both monoclonal antibodies (mAbs) and bispecific antibodies (biAbs) are important therapeutic tools.